Sugammadex: Cyclodextrins, Development of Selective Binding Agents, Pharmacology, Clinical Development, and Future Directions

2010 ◽  
Vol 28 (4) ◽  
pp. 691-708 ◽  
Author(s):  
Arezou Sadighi Akha ◽  
Joseph Rosa ◽  
Jonathan S. Jahr ◽  
Alvin Li ◽  
Kianusch Kiai
Keyword(s):  
Clinical Development ◽  
Future Directions ◽  
Selective Binding ◽  
Binding Agents

scholarly journals Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity

2019 ◽  
Vol 7 (8) ◽  
pp. 255 ◽  
Author(s):  
Stewart ◽  
Triccas ◽  
Petrovsky
Keyword(s):  
Infectious Agent ◽  
Mechanisms Of Action ◽  
Clinical Development ◽  
World Health ◽  
Effective Vaccine ◽  
Bacillus Calmette Guerin ◽  
Mycobacterium Tuberculosis Infection ◽  
Future Directions ◽  
Vaccine Protection ◽  
Health Organization

Tuberculosis (TB) caused by Mycobacterium tuberculosis infection is responsible for the most deaths by a single infectious agent worldwide, with 1.6 million deaths in 2017 alone. The World Health Organization, through its “End TB” strategy, aims to reduce TB deaths by 95% by 2035. In order to reach this goal, a more effective vaccine than the Bacillus Calmette-Guerin (BCG) vaccine currently in use is needed. Subunit TB vaccines are ideal candidates, because they can be used as booster vaccinations for individuals who have already received BCG and would also be safer for use in immunocompromised individuals in whom BCG is contraindicated. However, subunit TB vaccines will almost certainly require formulation with a potent adjuvant. As the correlates of vaccine protection against TB are currently unclear, there are a variety of adjuvants currently being used in TB vaccines in preclinical and clinical development. This review describes the various adjuvants in use in TB vaccines, their effectiveness, and their proposed mechanisms of action. Notably, adjuvants with less inflammatory and reactogenic profiles that can be administered safely via mucosal routes, may have the biggest impact on future directions in TB vaccine design.

scholarly journals Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer

Breast Care ◽  
2016 ◽  
Vol 11 (3) ◽  
pp. 167-173 ◽  
Author(s):  
Romualdo Barroso-Sousa ◽  
Geoffrey I. Shapiro ◽  
Sara M. Tolaney
Keyword(s):  
Breast Cancer ◽  
Single Agent ◽  
Progression Free Survival ◽  
Clinical Development ◽  
New Drugs ◽  
Future Directions ◽  
Free Survival ◽  
Cyclin Dependent Kinases ◽  
Hormone Receptor Positive ◽  
Central Nervous System Penetration

Clinical and preclinical data support a significant role for inhibitors of the cyclin-dependent kinases (CDKs) 4 and 6 in the treatment of patients with breast cancer. Recently, based on data showing improvement in progression-free survival, the use of palbociclib (Ibrance; Pfizer, Inc.) in combination with endocrine agents was approved to treat patients with hormone receptor-positive advanced disease. Importantly, 2 other CDK4/6 inhibitors, abemaciclib (LY2835219; Lilly) and ribociclib (LEE011; Novartis), are in the late stage of clinical development. In this review, we will focus on clinical data on these 2 new drugs, highlighting their differences compared to palbociclib in terms of single-agent activity, central nervous system penetration, and common adverse events. In addition, we will present the ongoing clinical trials and discuss future directions in the field.

Metal complexes as structure-selective binding agents for nucleic acids

2009 ◽  
Vol 253 (15-16) ◽  
pp. 2021-2035 ◽  
Author(s):  
F. Richard Keene ◽  
Jayden A. Smith ◽  
J. Grant Collins
Keyword(s):  
Nucleic Acids ◽  
Metal Complexes ◽  
Selective Binding ◽  
Binding Agents

Dicatonic 2,4-diaryl pyrimidines as DNA selective binding agents

1994 ◽  
Vol 4 (24) ◽  
pp. 2913-2918 ◽  
Author(s):  
Arvind Kumar ◽  
Min Zhao ◽  
W. David Wilson ◽  
David W. Boykin
Keyword(s):  
Selective Binding ◽  
Binding Agents

Panitumumab: a summary of clinical development in colorectal cancer and future directions

2012 ◽  
Vol 8 (4) ◽  
pp. 373-389 ◽  
Author(s):  
Guillem Argiles ◽  
Rodrigo Dienstmann ◽  
Elena Elez ◽  
Josep Tabernero
Keyword(s):  
Colorectal Cancer ◽  
Clinical Development ◽  
Future Directions

scholarly journals Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions

2019 ◽  
Vol Volume 12 ◽  
pp. 7857-7864 ◽  
Author(s):  
Christoph Jakob Ackermann ◽  
Gustavo Stock ◽  
Rebecca Tay ◽  
Mohammed Dawod ◽  
Fabio Gomes ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Development ◽  
Small Cell ◽  
Small Cell Lung ◽  
Future Directions

Interview With Francine Shapiro: Historical Overview, Present Issues, and Future Directions of EMDR

2009 ◽  
Vol 3 (4) ◽  
pp. 217-231 ◽  
Author(s):  
Marilyn Luber ◽  
Francine Shapiro
Keyword(s):  
Crisis Intervention ◽  
Somatoform Disorders ◽  
Current Treatment ◽  
Clinical Development ◽  
Historical Overview ◽  
Therapeutic Approaches ◽  
Future Directions ◽  
Wide Range ◽  
Distinct Features

This interview with Dr. Francine Shapiro, originator and developer of Eye Movement Desensitization and Reprocessing (EMDR), provides an overview of the history and evolution of EMDR from its inception to current findings and utilization, as well as future directions in research and clinical development. Dr. Shapiro discusses the psychological traditions that informed the development of EMDR and the Adaptive Information model, as well as the implications for current treatment. The rationale for the application of EMDR to a wide range of disorders is discussed, as well as its integration with other therapeutic approaches. Topics include research on the role of eye movements, the use of EMDR with combat veterans, somatoform disorders, attachment issues, and the distinct features of EMDR that have allowed it to be used for crisis intervention worldwide.

Sign in / Sign up

Export Citation Format

Share Document